Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This study found that although both adults and adolescents with alopecia areata experience a significant quality of life impact from ≥50% scalp hair loss, the impact is greater for adolescents, as indicated by their higher Dermatology Life Quality Index scores.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This review discusses current treatment strategies for alopecia and highlights the potential of lipid-based nanoparticles to improve drug delivery to the scalp and hair follicles, noting their ability to enhance skin penetration and drug stability while outlining associated challenges and the need for further research.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

In this study, researchers found that CD4 T cells from the skin draining lymph nodes of mice with alopecia areata can transfer the disease to recipient mice, highlighting the key role of these cells and their interaction with CD8 T cells in the disease's development.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This review discusses alopecia, its pathophysiology, nanotechnology-based drug delivery systems, and related quality of life issues, without reporting new clinical results.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

Understanding skin structure and development helps diagnose and treat skin disorders.

This study found that obesity in women may impair endometrial stromal function and contribute to reproductive complications, possibly due to metabolic influences rather than immune cell differences.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study conducted a survey among consultant dermatologists in Ireland to explore their use of JAK inhibitors for treating alopecia areata, acknowledging challenges posed by the lack of global guidelines and long-term safety data.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.